Ph II Early BC Pre-Surgical Biologic Study
Study identifier:1839IL/0219
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A PreSurgical Study to Evaluate Molecular Alterations that occur in Human Breast Cancer tissue and Normal Skin after Short Term Exposure to ZD1839 (IRESSA) and to correlate these alterations with Pharmacokinetic Parameters.
Medical condition
Breast Cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Gefitinib
Sex
Female
Actual Enrollment
65
Study type
Interventional
Age
18 Years - 150 Years
Date
Study Start Date: 01 Jul 2003
Primary Completion Date: -
Study Completion Date: 01 Feb 2005
Study design
Allocation: N/A
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Breast Cancer International Research Group
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
